γ-Secretase, apolipoprotein E and cellular cholesterol metabolism

Current Alzheimer Research

Volumn 9, Issue 2, 2012, Pages 189-199

  Walter, Jochen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer disease; Lipoproteins; Membane lipids; Secretase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ASPARTIC PROTEINASE; CELL PROTEIN; CHOLESTEROL; CLUSTERIN; GAMMA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN RECEPTOR; MEMBRANE LIPID; PRESENILIN;

ALZHEIMER DISEASE; ARTERIOSCLEROSIS; BRAIN HEMORRHAGE; CHOLESTEROL METABOLISM; COGNITION; ENDOCYTOSIS; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEAD INJURY; LIPID METABOLISM; LOSS OF FUNCTION MUTATION; NERVE CELL DIFFERENTIATION; NEUROPHYSIOLOGY; ONSET AGE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; APOLIPOPROTEINS E; CHOLESTEROL; HUMANS;

EID: 84857760693     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512799361583     Document Type: Review

References (178)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-66 (2001).
2. George-Hyslop PS, Rossor M. Alzheimer's disease. Unravelling the disease process. Lancet 358: Suppl:S1 (2001).
3. Annaert W, de Strooper B. A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 18: 25-51 (2002).
4. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 11: 585-90 (2001).
5. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-6 (1987).
6. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-5 (1992).
7. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258:126-9 (1992).
8. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-41 (1999).
9. Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275: 20647-51 (2000).
10. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as betasecretase. Mol Cell Neurosci 14: 419-27 (1999).
11. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity [see comments]. Nature 402:533-7 (1999).
12. Vassar R, Citron M. Abeta-generating enzymes: recent advances in beta-and gamma-secretase research. Neuron 27: 419-22 (2000).
13. Haass C, Steiner H. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol 12: 556-562 (2002).
14. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. Aph-1 and pen-2 Are Required for Notch Pathway Signaling, gamma-Secretase Cleavage of betaAPP, and Presenilin Protein Accumulation. Dev Cell 3: 85-97 (2002).
15. Tolia A, De SB. Structure and function of gamma-secretase. Semin Cell Dev Biol 20: 211-218 (2009).
16. Sisodia SS, George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3: 281-290 (2002).
17. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398: 513-7 (1999).
18. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9: 768-778 (2008).
19. Roses AD. On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis 9: 361-366 (2006).
20. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. Hum Mol Genet 18: R137-R145 (2009).
21. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement.Geriatr Cogn Disord 28: 75-80 (2009).
22. Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res 28: 630-636 (2006).
23. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 6: 345-351 (2003).
24. Sabbagh MN, Thind K, Sparks DL. On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks. Alzheimer Dis Assoc Disord 23: 303-305 (2009).
25. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443 (2000).
26. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356: 1627-1631 (2000).
27. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80:13-17 (2009).
28. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62:753-757 (2005).
29. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856-5861 (2001).
30. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74: 956-964 (2010).
31. Shepherd CE, Grace EM, Mann DM, Halliday GM. Relationship between neuronal loss and 'inflammatory plaques' in early onset Alzheimer's disease. Neuropathol Appl Neurobiol 33: 328-333 (2007).
32. Trompet S, van VP, de Craen AJ, Jolles J, Buckley BM, Murphy MB, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257: 85-90 (2010).
33. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 110: 597-603 (2002).
34. Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci 24:S45-S48 (2001).
35. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167: 953-960 (2004).
36. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. From the Cover: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 98:5815-20 (2001).
37. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113-123 (2003).
38. Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts. Nat Clin Pract Neurol 3: 374-382 (2007).
39. Huttunen HJ, Kovacs DM. ACAT as a drug target for Alzheimer's disease. Neurodegener Dis 5:212-214.
40. Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, George-Hyslop P. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 302:822-826 (2003).
41. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17-23 (2007).
42. Di FG, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323:1473-1477 (2009).
43. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89: 629-39 (1997).
44. Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 387: 288-92 (1997).
45. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 96:11872-7 (1999).
46. Naruse S, Thinakaran G, Luo JJ, Kusiak JW, Tomita T, Iwatsubo T, et al. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 21:1213-21 (1998).
47. Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, et al. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron 32: 579-89 (2001).
48. Prager K, Wang-Eckhardt L, Fluhrer R, Killick R, Barth E, Hampel H, et al. A structural switch of presenilin 1 by glycogen synthase kinase 3beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling. J Biol Chem 282:14083-14093 (2007).
49. Georgakopoulos A, Marambaud P, Efthimiopoulos S, Shioi J, Cui W, Li HC, et al. Presenilin-1 forms complexes with the cadherin/ catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Mol Cell 4: 893-902 (1999).
50. Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, et al. Presenilin 1 facilitates the constitutive turnover of betacatenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway. J Neurosci 19: 4229-37 (1999).
51. Walter J, Schindzielorz A, Grunberg J, Haass C. Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis. Proc Natl Acad Sci USA 96:1391-6 (1999).
52. Fluhrer R, Friedlein A, Haass C, Walter J. Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis. J Biol Chem 279:1585-1593 (2004).
53. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, Sunderland T, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 274:1710-1713 (1996).
54. Roperch JP, Alvaro V, Prieur S, Tuynder M, Nemani M, Lethrosne F, et al. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat Med 4: 835-838 (1998).
55. Alves dC, Paitel E, Mattson MP, Amson R, Telerman A, Ancolio K, et al. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc Natl Acad Sci USA 99: 4043-4048 (2002).
56. Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci USA 93:14940-4 (1996).
57. Baumeister R, Leimer U, Zweckbronner I, Jakubek C, Grunberg J, Haass C. Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. Genes Funct 1:149-59 (1997).
58. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-70 (1996).
59. Citron M, Eckman CB, Diehl TS, Corcoran C, Ostaszewski BL, Xia W, et al. Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis 5:107-116 (1998).
60. Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad SciUSA 94:2025-2030 (1997).
61. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96:732-742 (2006).
62. Kulic L, Walter J, Multhaup G, Teplow DB, Baumeister R, Romig H, et al. Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of Notch. Proc Natl Acad Sci USA 97:5913-8 (2000).
63. Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA 99: 8025-8030 (2002).
64. De SB. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8:141-146 (2007).
65. Shen J, Kelleher RJ, III: The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 104: 403-409 (2007).
66. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr. Alzheimer Res 3: 81-90 (2006).
67. Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain-and loss-of-function in neurodegenerative diseases. EMBO J 27: 336-349 (2008).
68. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29:13042-13052 (2009).
69. Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM. {gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE. J Biol Chem 282: 23639-23644 (2007).
70. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923 (1993).
71. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102 (1993).
72. Saunders AM, Roses AD. Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke 24:1416-1417 (1993).
73. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 31: 445-454 (2006).
74. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28:11445-11453 (2008).
75. Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, et al. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J Biol Chem 277: 50380-50385 (2002).
76. Asada T, Kariya T, Yamagata Z, Kinoshita T, Asaka A: ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease. Neurology 1996, 47:603.
77. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB: Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998, 51:149-153.
78. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 47:444-448 (1996).
79. Kurz A, Egensperger R, Haupt M, Lautenschlager N, Romero B, Graeber MB, et al. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 47: 440-443 (1996).
80. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 62: 454-459 (2005).
81. Wijsman EM, Daw EW, Yu X, Steinbart EJ, Nochlin D, Bird TD, et al. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet 132 B:14-20 (2005).
82. Ang LS, Cruz RP, Hendel A, Granville DJ. Apolipoprotein E, an important player in longevity and age-related diseases. Exp Gerontol 43: 615-622 (2008).
83. Bennet AM, Di AE, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298:1300-1311 (2007).
84. Asada T, Kariya T, Yamagata Z, Kinoshita T, Asaka A. Apolipoprotein E allele in centenarians. Neurology 46:1484 (1996).
85. Louhija J, Miettinen HE, Kontula K, Tikkanen MJ, Miettinen TA, Tilvis RS. Aging and genetic variation of plasma apolipoproteins. Relative loss of the apolipoprotein E4 phenotype in centenarians. Arterioscler Thromb 14:1084-1089 (1994).
86. Panza F, Solfrizzi V, Torres F, Mastroianni F, Del PA, Colacicco AM, et al. Decreased frequency of apolipoprotein E epsilon4 allele from Northern to Southern Europe in Alzheimer's disease patients and centenarians. Neurosci Lett 277: 53-56 (1999).
87. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6: 29-32 (1994).
88. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 390: 287-293 (2009).
89. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 63:287-303 (2009).
90. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10: 333-344 (2009).
91. Mulder M. Sterols in the central nervous system. Curr Opin Clin Nutr Metab Care 12:152-158 (2009).
92. Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25:72-78 (2003).
93. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26: 4985-4994 (2006).
94. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J BiolChem 279: 40987-40993 (2004).
95. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279: 41197-41207 (2004).
96. Vance JE, Karten B, Hayashi H. Lipid dynamics in neurons. Biochem Soc rans 34: 399-403 (2006).
97. Rebeck GW. Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J Mol Neurosci 23: 219-224 (2004).
98. Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, Kim TW, et al. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J 22: 1073-1082 (2008).
99. Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci 29:190-201 (2005).
100. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294:1354-1357 (2001).
101. Nieweg K, Schaller H, Pfrieger FW. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 109:125-134 (2009).
102. Kretz O, Fester L, Wehrenberg U, Zhou L, Brauckmann S, Zhao S, et al. Hippocampal synapses depend on hippocampal estrogen synthesis. J Neurosci 24: 5913-5921 (2004).
103. Hu R, Cai WQ, Wu XG, Yang Z. Astrocyte-derived estrogen enhances synapse formation and synaptic transmission between cultured neonatal rat cortical neurons. Neuroscience 144:1229-1240 (2007).
104. Tournell CE, Bergstrom RA, Ferreira A. Progesterone-induced agrin expression in astrocytes modulates glia-neuron interactions leading to synapse formation. Neuroscience 141:1327-1338 (2006).
105. Nixon RA. Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am J Pathol 164:757-761 (2004).
106. Distl R, Treiber-Held S, Albert F, Meske V, Harzer K, Ohm TG. Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J Pathol 200:104-111 (2003).
107. Suresh S, Yan Z, Patel RC, Patel YC, Patel SC. Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D. J Neurochem 70: 242-251 (1998).
108. Ong WY, Kumar U, Switzer RC, Sidhu A, Suresh G, Hu CY, et al. Neurodegeneration in Niemann-Pick type C disease mice. Exp Brain Res 141:218-231 (2001).
109. Vincent I, Bu B, Erickson RP. Understanding Niemann-Pick type C disease: a fat problem. Curr Opin Neurol 16:155-161 (2003).
110. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164: 975-985 (2004).
111. Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci 23: 5645-5649 (2003).
112. Goldstein JL, Bose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 124:35-46 (2006).
113. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA 99:13878-13883 (2002).
114. Repa JJ, Li H, Frank-Cannon TC, Valasek MA, Turley SD, Tansey MG, et al. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 27:14470-14480 (2007).
115. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, et al. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem 281:12799-12808 (2006).
116. Quan G, Xie C, Dietschy JM, Turley SD. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res Dev Brain Res 146: 87-98 (2003).
117. Fagan AM, Murphy BA, Patel SN, Kilbridge JF, Mobley WC, Bu G, et al. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Exp Neurol 151: 314-325 (1998).
118. Anderson R, Barnes JC, Bliss TV, Cain DP, Cambon K, Davies HA, et al. Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience 85: 93-110 (1998).
119. Gordon I, Grauer E, Genis I, Sehayek E, Michaelson DM. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 199: 1-4 (1995).
120. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 136:107-122 (1995).
121. Masliah E, Samuel W, Veinbergs I, Mallory M, Mante M, Saitoh T. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res 751: 307-314 (1997).
122. Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein Edeficient mouse. Annu Rev Nutr 15: 495-518 (1995).
123. Sabo T, Lomnitski L, Nyska A, Beni S, Maronpot RR, Shohami E, et al. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 101: 879-884 (2000).
124. Slooter AJ, Tang MX, van Duijn CM, Stern Y, Ott A, Bell K, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 277: 818-821 (1997).
125. McCarron MO, Hoffmann KL, DeLong DM, Gray L, Saunders AM, Alberts MJ. Intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma, and edema volumes. Neurology 53: 2176-2179 (1999).
126. Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 67: 261-270 (2008).
127. Hoe HS, Pocivavsek A, Dai H, Chakraborty G, Harris DC, Rebeck GW. Effects of apoE on neuronal signaling and APP processing in rodent brain. Brain Res 1112:70-79 (2006).
128. Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem 93:145-155 (2005).
129. Martin AM, Kuhlmann C, Trossbach S, Jaeger S, Waldron E, Roebroek A, et al. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J Biol Chem 283:12004-12013 (2008).
130. Hoe HS, Pocivavsek A, Chakraborty G, Fu Z, Vicini S, Ehlers MD, et al. Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor. J Biol Chem 281: 3425-3431 (2006).
131. Korwek KM, Trotter JH, LaDu MJ, Sullivan PM, Weeber EJ. ApoE isoform-dependent changes in hippocampal synaptic function. Mol Neurodegener 4: 21 (2009).
132. Weisgraber KH, Roses AD, Strittmatter WJ. The role of apolipoprotein E in the nervous system. Curr Opin Lipidol 5:110-116 (1994).
133. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 58: 681-693 (2008).
134. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 29: 431-438 (2009).
135. Willnow TE, Nykjaer A, Herz J. Lipoprotein receptors: new roles for ancient proteins. Nat Cell Biol 1: E157-E162 (1999).
136. Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J.Lipid Res 46:1721-1731 (2005).
137. Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem 80: 25754-25759 (2005).
138. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64: 632-644 (2009).
139. Taha AY, Chen CT, Liu Z, Kim JH, Mount HT, Bazinet RP. Brainstem concentrations of cholesterol are not influenced by genetic ablation of the low-density lipoprotein receptor. Neurochem Res34: 311-315 (2009).
140. Elder GA, Cho JY, English DF, Franciosi S, Schmeidler J, Sosa MA, et al. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J Neurochem 102:1220-1231 (2007).
141. Mulder M, Koopmans G, Wassink G, Al MG, Simard ML, Havekes LM, et al. LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus. Neurosci Res 59: 251-256 (2007).
142. Mulder M, Jansen PJ, Janssen BJ, van de Berg WD, van der BH, Havekes LM, et al. Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol Dis 16: 212-219 (2004).
143. Wood WG, Igbavboa U, Eckert GP, Johnson-Anuna LN, Muller WE. Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol Neurobiol 31:185-192 (2005).
144. Waldron E, Jaeger S, Pietrzik CU. Functional role of the lowdensity lipoprotein receptor-related protein in Alzheimer's disease. Neurodegener Dis 3: 233-238 (2006).
145. Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem 71: 405-434 (2002).
146. May P, Bock HH, Herz J. Integration of endocytosis and signal transduction by lipoprotein receptors. Sci STKE 2003: E12 (2003).
147. May P, Rohlmann A, Bock HH, Zurhove K, Marth JD, Schomburg ED, et al. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol 24:8872-8883 (2004).
148. Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, et al. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 101:1075-1080 (2004).
149. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 82: 331-340 (1995).
150. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 24:4259-4265 (2004).
151. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, et al. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem 281: 36180-36186 (2006).
152. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G. The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 279: 29639-29646 (2004).
153. Marzolo MP, Bu G. Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. Semin Cell Dev Biol 20:191-200 (2009).
154. Schmidt V, Sporbert A, Rohe M, Reimer T, Rehm A, Andersen OM, et al. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J Biol Chem 282:32956-32964 (2007).
155. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 102:13461-13466 (2005).
156. Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, et al. Loss of LR11/SORLA Enhances Early Pathology in a Mouse Model of Amyloidosis: Evidence for a Proximal Role in Alzheimer's Disease. J Neurosci 28:12877-12886 (2008).
157. May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem 277:18736-18743 (2002).
158. Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol 6: e257 (2008).
159. Zurhove K, Nakajima C, Herz J, Bock HH, May P: Gammasecretase limits the inflammatory response through the processing of LRP1. Sci.Signal. 2008, 1:ra15.
160. Cheng D, Huang R, Lanham IS, Cathcart HM, Howard M, Corder EH, et al. Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease. J Med Genet 42:129-131 (2005).
161. Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, Bennett DA, et al. Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiol Aging 26:1-7 (2005).
162. Retz W, Thome J, Durany N, Harsanyi A, Retz-Junginger P, Kornhuber J, et al. Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr Genet 11:115-122 (2001).
163. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid betapeptide deposition. Nat Genet 17: 263-264 (1997).
164. Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, Hyman BT. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol 100: 451-458 (2000).
165. Demattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 99:10843-10848 (2002).
166. Holtzman DM. In vivo effects of ApoE and clusterin on amyloidbeta metabolism and neuropathology. J Mol Neurosci 23:247-254 (2004).
167. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47: 739-747 (2000).
168. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9: 305-318 (2002).
169. Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci 22:10539-10548 (2002).
170. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 29: 6771-6779 (2009).
171. Dolev I, Michaelson DM. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci USA 101:13909-13914 (2004).
172. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118: 4002-4013 (2008).
173. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol. 2005, 7:1118-1123.
174. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56:66-78 (2007).
175. Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, et al. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci 28:12097-12106 (2008).
176. Winkler E, Hobson S, Fukumori A, Dumpelfeld B, Luebbers T, Baumann K, et al. Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human gamma-secretase. Biochemistry 48:1183-1197 (2009).
177. Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, et al. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22:1679-1689 (2002).
178. Yamazaki T, Chang TY, Haass C, Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemannpick type C cells. J Biol Chem 276: 4454-4460 (2001).